A review of alternative promoters for optimal recombinant protein expression in baculovirus-infected insect cells

Grose, Carissa; Putman, Zoe; Esposito, Dominic

doi:10.1016/j.pep.2021.105924

Cited by 22 publications

(18 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some members of this family, such as the Cydia pomonella Granulovirus (CpGV), have even been approved in the European Union (EU) under Regulation (EC) No 1107/2009 as active substance for insect pest control. Furthermore, baculoviruses are widely used as expression systems for the production and characterization of recombinant proteins, multi-protein complexes like virus-like particles and vaccines in insect cells (Chu & Quan 2021;Grose et al 2021). Bombyx mori nucleopolyhedrovirus (BmNPV) or Autographa californica multiple nucleopolyhedrovirus (AcMNPV) are commonly used viral vectors for protein expression in several Lepidopteran cell lines.…”

Section: Baculovirusmentioning

confidence: 99%

Engineering strategies for insect viruses and microbes for dsRNA production and delivery to insects for targeted gene silencing

Xue¹,

Santos²,

Smagghe³

et al. 2023

entomologia

View full text Add to dashboard Cite

RNA interference (RNAi)-based pest control is viewed as a safe and effective method for insect pest control. However, the stability and efficient cellular delivery of the double stranded RNA (dsRNA) active molecule remains crucial to its success in pest control. Among the different approaches that have been proposed to improve dsRNA delivery in insects, the use of nano-carriers, engineered viruses and engineered microbes have been successfully employed in proofof-concept studies. This review focuses on engineering approaches that have been successfully employed to modify insect viruses and different microbes for dsRNA production and delivery in insects. First, the different viral vector systems based on insect RNA and DNA viruses for dsRNA delivery are discussed. Second, a comprehensive overview of different microbe-based (bacteria, fungi, microalgae) dsRNA production and delivery systems that have been developed till date are presented. Finally, future perspectives on the development of other delivery systems with potential in the context of insect pest control are provided. Overall, this review is expected to stimulate awareness, interest, insight and research into promising sources of biotechnologically interesting viruses and microbes for protecting agriculture and human health against insect pests.

show abstract

Section: Baculovirusmentioning

confidence: 99%

Engineering strategies for insect viruses and microbes for dsRNA production and delivery to insects for targeted gene silencing

Xue¹,

Santos²,

Smagghe³

et al. 2023

entomologia

View full text Add to dashboard Cite

show abstract

“…In addition, BEVS induces an immune response that produces inflammatory cytokines and chemokines and activates the Scotti et al (1996) Frontiers in Bioengineering and Biotechnology frontiersin.org complement pathway (Betenbaugh et al, 1996). This, in turn, can lead to viral genome degradation, suppressed transgene expression, unstable protein expression and baculovirus genome instability (Grose et al, 2021). Any of these issues may limit the further development of BEVS.…”

Section: The Advantages and Limitations Of Baculovirus Expression Vec...mentioning

confidence: 99%

Genetic engineering of baculovirus-insect cell system to improve protein production

Hong

Li²,

Xue³

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

The Baculovirus Expression Vector System (BEVS), a mature foreign protein expression platform, has been available for decades, and has been effectively used in vaccine production, gene therapy, and a host of other applications. To date, eleven BEVS-derived products have been approved for use, including four human vaccines [Cervarix against cervical cancer caused by human papillomavirus (HPV), Flublok and Flublok Quadrivalent against seasonal influenza, Nuvaxovid/Covovax against COVID-19], two human therapeutics [Provenge against prostate cancer and Glybera against hereditary lipoprotein lipase deficiency (LPLD)] and five veterinary vaccines (Porcilis Pesti, BAYOVAC CSF E2, Circumvent PCV, Ingelvac CircoFLEX and Porcilis PCV). The BEVS has many advantages, including high safety, ease of operation and adaptable for serum-free culture. It also produces properly folded proteins with correct post-translational modifications, and can accommodate multi-gene– or large gene insertions. However, there remain some challenges with this system, including unstable expression and reduced levels of protein glycosylation. As the demand for biotechnology increases, there has been a concomitant effort into optimizing yield, stability and protein glycosylation through genetic engineering and the manipulation of baculovirus vector and host cells. In this review, we summarize the strategies and technological advances of BEVS in recent years and explore how this will be used to inform the further development and application of this system.

show abstract

“…Other features to improve gene expression through promoter optimization, combination of promoters, and/or use of enhancers have been described in the literature and were recently reviewed by Grose et al [35]. For example, target protein production can be improved when duplicating the burst sequence compared to the polyhedrin promoter alone [36] and inserting the enhancer homologous region 1 (HR1) increased polyhedrin expression by 11-fold when placed downstream from the luciferase reporter gene [37].…”

Section: Baculovirus Acnpv Backbone and Transfer Vector Developmentmentioning

confidence: 99%

Innovations in the Insect Cell Expression System for Industrial Recombinant Vaccine Antigen Production

Cox¹

2021

Vaccines

View full text Add to dashboard Cite

The insect cell expression system has previously been proposed as the preferred biosecurity strategy for production of any vaccine, particularly for future influenza pandemic vaccines. The development and regulatory risk for new vaccine candidates is shortened as the platform is already in use for the manufacturing of the FDA-licensed seasonal recombinant influenza vaccine Flublok®. Large-scale production capacity is in place and could be used to produce other antigens as well. However, as demonstrated by the 2019 SARS-CoV-2 pandemic the insect cell expression system has limitations that need to be addressed to ensure that recombinant antigens will indeed play a role in combating future pandemics. The greatest challenge may be the ability to produce an adequate quantity of purified antigen in an accelerated manner. This review summarizes recent innovations in technology areas important for enhancing recombinant-protein production levels and shortening development timelines. Opportunities for increasing product concentrations through vector development, cell line engineering, or bioprocessing and for shortening timelines through standardization of manufacturing processes will be presented.

show abstract

A review of alternative promoters for optimal recombinant protein expression in baculovirus-infected insect cells

Cited by 22 publications

References 100 publications

Engineering strategies for insect viruses and microbes for dsRNA production and delivery to insects for targeted gene silencing

Engineering strategies for insect viruses and microbes for dsRNA production and delivery to insects for targeted gene silencing

Genetic engineering of baculovirus-insect cell system to improve protein production

Innovations in the Insect Cell Expression System for Industrial Recombinant Vaccine Antigen Production

Contact Info

Product

Resources

About